IN2012CH01573A - - Google Patents

Download PDF

Info

Publication number
IN2012CH01573A
IN2012CH01573A IN1573CH2012A IN2012CH01573A IN 2012CH01573 A IN2012CH01573 A IN 2012CH01573A IN 1573CH2012 A IN1573CH2012 A IN 1573CH2012A IN 2012CH01573 A IN2012CH01573 A IN 2012CH01573A
Authority
IN
India
Prior art keywords
compounds
bruton
btk
formula
tyrosine kinase
Prior art date
Application number
Other languages
English (en)
Inventor
Mahesh Thakkar
Summon Koul
Debnath Bhuniya
Kasim Mookhtiar
Original Assignee
Advinus Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Advinus Therapeutics Ltd filed Critical Advinus Therapeutics Ltd
Priority to CN201380019452.8A priority Critical patent/CN104662018B/zh
Priority to CA2869954A priority patent/CA2869954C/en
Priority to EP13737672.9A priority patent/EP2838898B1/en
Priority to IN1573CH2012 priority patent/IN2012CH01573A/en
Priority to JP2015506355A priority patent/JP6182593B2/ja
Priority to AU2013250726A priority patent/AU2013250726B2/en
Priority to PCT/IN2013/000259 priority patent/WO2013157022A1/en
Priority to US14/509,793 priority patent/US9233983B2/en
Priority to ZA2014/07341A priority patent/ZA201407341B/en
Priority to IL235146A priority patent/IL235146A/en
Publication of IN2012CH01573A publication Critical patent/IN2012CH01573A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
IN1573CH2012 2012-04-20 2013-04-18 IN2012CH01573A (ja)

Priority Applications (10)

Application Number Priority Date Filing Date Title
CN201380019452.8A CN104662018B (zh) 2012-04-20 2013-04-18 取代的杂双环化合物、组合物及其医疗应用
CA2869954A CA2869954C (en) 2012-04-20 2013-04-18 Substituted hetero-bicyclic compounds, compositions and medicinal applications thereof in medical conditions related to modulation of bruton's tyrosine kinase activity
EP13737672.9A EP2838898B1 (en) 2012-04-20 2013-04-18 Substituted hetero-bicyclic compounds, compositions and medicinal applications thereof
IN1573CH2012 IN2012CH01573A (ja) 2012-04-20 2013-04-18
JP2015506355A JP6182593B2 (ja) 2012-04-20 2013-04-18 置換ヘテロ二環化合物、組成物及び医薬並びにそれらの用途
AU2013250726A AU2013250726B2 (en) 2012-04-20 2013-04-18 Substituted hetero-bicyclic compounds, compositions and medicinal applications thereof
PCT/IN2013/000259 WO2013157022A1 (en) 2012-04-20 2013-04-18 Substituted hetero-bicyclic compounds, compositions and medicinal applications thereof
US14/509,793 US9233983B2 (en) 2012-04-20 2014-10-08 Substituted hetero-bicyclic compounds, compositions and medicinal applications thereof
ZA2014/07341A ZA201407341B (en) 2012-04-20 2014-10-09 Substituted hetero-bicyclic compounds, compositions and medicinal applications thereof
IL235146A IL235146A (en) 2012-04-20 2014-10-19 Converted heterocyclic compounds, preparations and their medical applications

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN1573CH2012 IN2012CH01573A (ja) 2012-04-20 2013-04-18

Publications (1)

Publication Number Publication Date
IN2012CH01573A true IN2012CH01573A (ja) 2015-07-10

Family

ID=48794150

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1573CH2012 IN2012CH01573A (ja) 2012-04-20 2013-04-18

Country Status (10)

Country Link
US (1) US9233983B2 (ja)
EP (1) EP2838898B1 (ja)
JP (1) JP6182593B2 (ja)
CN (1) CN104662018B (ja)
AU (1) AU2013250726B2 (ja)
CA (1) CA2869954C (ja)
IL (1) IL235146A (ja)
IN (1) IN2012CH01573A (ja)
WO (1) WO2013157022A1 (ja)
ZA (1) ZA201407341B (ja)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2571361A4 (en) 2010-05-19 2013-11-13 Univ North Carolina PYRAZOLOPYRIMIDINE COMPOUNDS FOR CANCER TREATMENT
CN103958510B (zh) 2011-10-03 2016-10-19 北卡罗来纳大学教堂山分校 用于治疗癌症的吡咯并嘧啶化合物
CN104302627A (zh) 2012-05-22 2015-01-21 北卡罗来纳大学教堂山分校 用于治疗癌症的嘧啶化合物
BR112015002590A2 (pt) 2012-08-10 2019-08-06 Boehringer Ingelheim Int compostos heteroaromáticos como inibidores de tirosina cinase de bruton (btk)
US9562047B2 (en) 2012-10-17 2017-02-07 The University Of North Carolina At Chapel Hill Pyrazolopyrimidine compounds for the treatment of cancer
EP2925752A4 (en) 2012-11-27 2016-06-01 Univ North Carolina PYRIMIDINE COMPOUNDS FOR CANCER TREATMENT
AU2014231567A1 (en) * 2013-03-14 2015-10-01 Abbvie Inc. Pyrrolo[2,3-b]pyridine CDK9 kinase inhibitors
CN104211703B (zh) * 2013-05-30 2018-04-03 南京勇山生物科技有限公司 一类作为布鲁顿激酶抑制剂的稠杂环化合物
US9512084B2 (en) 2013-11-29 2016-12-06 Novartis Ag Amino pyrimidine derivatives
US20150291606A1 (en) * 2014-04-11 2015-10-15 The University Of North Carolina At Chapel Hill Mertk-specific pyrrolopyrimidine compounds
CN105294571B (zh) * 2014-07-03 2019-04-23 浙江九洲药业股份有限公司 一种依鲁替尼中间体及其制备方法和用途
WO2016020295A1 (en) 2014-08-04 2016-02-11 Nuevolution A/S Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases
RU2742122C2 (ru) 2014-10-06 2021-02-02 Мерк Патент Гмбх Соединения гетероарила в качестве ингибиторов ткб и их применение
US10272070B2 (en) 2014-10-14 2019-04-30 The Board of Trustees of the Leland Stanford Junio r University Method for treating neurodegenerative diseases
DK3209656T3 (da) * 2014-10-24 2020-07-13 Bristol Myers Squibb Co Indolcarboxamidforbindelser, der er anvendelige som kinasehæmmere
EP3042903B1 (en) * 2015-01-06 2019-08-14 Impetis Biosciences Ltd. Substituted hetero-bicyclic compounds, compositions and medicinal applications thereof
PE20180572A1 (es) 2015-06-18 2018-04-04 Cephalon Inc Derivados de piperidina 1,4-sustituidos
ES2849951T3 (es) 2015-06-18 2021-08-24 89Bio Ltd Derivados de piperidina 4-bencil y 4-benzoil sustituidos
GB201517217D0 (en) * 2015-09-29 2015-11-11 Astex Therapeutics Ltd And Cancer Res Technology Ltd Pharmaceutical compounds
GB201517216D0 (en) * 2015-09-29 2015-11-11 Cancer Res Technology Ltd And Astex Therapeutics Ltd Pharmaceutical compounds
EP3390367B1 (en) 2015-12-15 2020-09-09 The Board of Trustees of the Leland Stanford Junior University Method for preventing and/or treating aging-associated cognitive impairment and neuroinflammation
US10570118B2 (en) 2016-01-13 2020-02-25 Boehringer Ingelheim International Gmbh Isoquinolones as BTK inhibitors
US10709708B2 (en) 2016-03-17 2020-07-14 The University Of North Carolina At Chapel Hill Method of treating cancer with a combination of MER tyrosine kinase inhibitor and an epidermal growth factor receptor (EGFR) inhibitor
ES2957233T3 (es) 2016-04-15 2024-01-15 Blueprint Medicines Corp Inhibidores de quinasa tipo receptor de activina
CA2969295A1 (en) 2016-06-06 2017-12-06 Pfizer Inc. Substituted carbonucleoside derivatives, and use thereof as a prmt5 inhibitor
JP6954994B2 (ja) * 2016-08-16 2021-10-27 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ 可逆性ｂｔｋ阻害剤としてのオキソ−イミダゾピリジン及びその使用
KR102565546B1 (ko) 2016-11-25 2023-08-10 카나 바이오사이언스, 인코포레이션 신규 옥소이소퀴놀린 유도체
CN106883235B (zh) * 2016-12-29 2019-04-30 天津国际生物医药联合研究院 恶二唑类化合物的制备和应用
WO2018145525A1 (zh) * 2017-02-08 2018-08-16 中国医药研究开发中心有限公司 吡咯并芳杂环类化合物及其制备方法和医药用途
CN108794480A (zh) * 2017-04-28 2018-11-13 天津药物研究院有限公司 吡咯并嘧啶类化合物、其制备方法和用途
ES2931537T3 (es) 2017-10-18 2022-12-30 Blueprint Medicines Corp Pirrolopiridinas sustituidas como inhibidores de la quinasa similar al receptor de activina
PE20211444A1 (es) * 2017-12-13 2021-08-05 Lupin Ltd Componentes heterociclicos biciclicos sustituidos como inhibidores de prmt5
CN109293638B (zh) * 2018-03-27 2020-08-14 大连理工大学 一种增强型的靶向识别受体酪氨酸激酶的荧光传感器及细胞膜荧光成像的应用
CN108707154A (zh) * 2018-07-10 2018-10-26 刘凤娟 一种治疗癌症的药物溶剂合物及其制备方法
AU2019319745A1 (en) 2018-08-06 2021-03-25 The Board Of Trustees Of The Leland Stanford Junior University 2-arylbenzimidazoles as Ppargc1a activators for treating neurodegenerative diseases
JP2022502353A (ja) * 2018-09-06 2022-01-11 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft 自己免疫疾患の処置のための新規の環状アミジン化合物
CN109369619A (zh) * 2018-10-04 2019-02-22 南京先进生物材料与过程装备研究院有限公司 酞嗪酮类化合物晶型b及其制备方法
CN109180642A (zh) * 2018-10-04 2019-01-11 南京先进生物材料与过程装备研究院有限公司 酞嗪酮类btk抑制剂及其应用
CN109180643A (zh) * 2018-10-04 2019-01-11 南京先进生物材料与过程装备研究院有限公司 酞嗪酮类化合物晶型a及其制备方法
CN109485636A (zh) * 2018-10-04 2019-03-19 南京先进生物材料与过程装备研究院有限公司 一种新型btk激酶抑制剂的盐酸盐及其制备方法与用途
CN109336863A (zh) * 2018-10-04 2019-02-15 南京先进生物材料与过程装备研究院有限公司 一种新型酞嗪酮类btk抑制剂、制备及其应用
CN109293635A (zh) * 2018-10-04 2019-02-01 南京先进生物材料与过程装备研究院有限公司 一种新型btk激酶抑制剂的p晶型及其制备方法
CN109336864A (zh) * 2018-10-04 2019-02-15 南京先进生物材料与过程装备研究院有限公司 酞嗪酮类化合物晶型n及其制备方法
CN109180644A (zh) * 2018-10-04 2019-01-11 南京先进生物材料与过程装备研究院有限公司 一种新型btk激酶抑制剂的甲磺酸盐及其制备方法与用途
RS64972B1 (sr) * 2019-06-10 2024-01-31 Lupin Ltd Inhibitori prmt5
CN110305140B (zh) * 2019-07-30 2020-08-04 上海勋和医药科技有限公司 二氢吡咯并嘧啶类选择性jak2抑制剂
AU2020405446A1 (en) 2019-12-20 2022-05-26 Nuevolution A/S Compounds active towards nuclear receptors
WO2021198956A1 (en) 2020-03-31 2021-10-07 Nuevolution A/S Compounds active towards nuclear receptors
EP4126874A1 (en) 2020-03-31 2023-02-08 Nuevolution A/S Compounds active towards nuclear receptors
WO2022140246A1 (en) 2020-12-21 2022-06-30 Hangzhou Jijing Pharmaceutical Technology Limited Methods and compounds for targeted autophagy

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0115109D0 (en) 2001-06-21 2001-08-15 Aventis Pharma Ltd Chemical compounds
GB0115393D0 (en) 2001-06-23 2001-08-15 Aventis Pharma Ltd Chemical compounds
CN1523991A (zh) * 2001-08-10 2004-08-25 ��˹��ŵ�� 单独的c-Src抑制剂或其与STI571的组合用于治疗白血病的用途
DE60225316T2 (de) 2001-11-13 2009-02-26 AXYS Pharmaceuticals, Inc., South San Francisco Cyanoalkylamino-derivate als protease-hemmer
US20060183746A1 (en) * 2003-06-04 2006-08-17 Currie Kevin S Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds
CN101124227A (zh) * 2004-11-10 2008-02-13 Cgi制药有限公司 可用作激酶活性调节剂的咪唑并[1,2-a]吡嗪-8-基胺
ATE455103T1 (de) 2005-06-24 2010-01-15 Bristol Myers Squibb Co Als antikoagulationsmittel geeignete phenylglycinamid- und pyridylglycinamidderivate
EP1940843A4 (en) * 2005-08-11 2010-09-15 Ariad Pharma Inc UNSATURATED HETEROCYCLIC DERIVATIVES
AU2006284900A1 (en) 2005-08-29 2007-03-08 Vertex Pharmaceuticals Incorporated 3, 5-disubstituted pyrid-2-ones useful as inhibitors of Tec family of non-receptor tyrosine kinases
EP1963320A1 (en) 2005-12-07 2008-09-03 OSI Pharmaceuticals, Inc. Pyrrolopyridine kinase inhibiting compounds
US8895745B2 (en) 2006-12-22 2014-11-25 Astex Therapeutics Limited Bicyclic heterocyclic compounds as FGFR inhibitors
US7989465B2 (en) 2007-10-19 2011-08-02 Avila Therapeutics, Inc. 4,6-disubstituted pyrimidines useful as kinase inhibitors
CN101932573B (zh) 2008-02-05 2014-06-11 霍夫曼-拉罗奇有限公司 吡啶酮类和哒嗪酮类
WO2009114180A1 (en) 2008-03-13 2009-09-17 The General Hospital Corporation Inhibitors of the bmp signaling pathway
CA2725754C (en) 2008-06-11 2017-05-23 Hazel Joan Dyke Diazacarbazoles and methods of use
PE20110164A1 (es) 2008-07-02 2011-03-28 Hoffmann La Roche Nuevas fenilpirazinonas como inhibidores de quinasa
CA2728559A1 (en) 2008-07-03 2010-01-07 Exelixis Inc. Cdk modulators
WO2010005783A1 (en) 2008-07-08 2010-01-14 Boehringer Ingelheim International Gmbh Pyrrolidinyl and piperidinyl compounds useful as nhe-1 inhibitors
UY31984A (es) 2008-07-16 2010-02-26 Boehringer Ingelheim Int DERIVADOS DE 1-(3,4-difluorobencil)-6-oxo-1,6-dihidropirimidin-5-carboxamidas N-sustituidas y de 2-(3,4-difluorobencil)-3-oxo-2,3-dihidro-1H-pirazol-4-carboxamidas N-sustituidas.
WO2010006970A1 (en) 2008-07-18 2010-01-21 F. Hoffmann-La Roche Ag Novel phenylimidazopyrazines
WO2010048149A2 (en) 2008-10-20 2010-04-29 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
WO2010068806A1 (en) * 2008-12-10 2010-06-17 Cgi Pharmaceuticals, Inc. Amide derivatives as btk inhibitors in the treatment of allergic, autoimmune and inflammatory disorders as well as cancer
WO2010068788A1 (en) 2008-12-10 2010-06-17 Cgi Pharmaceuticals, Inc. Heterocyclic amides as btk inhibitors
WO2010068810A2 (en) 2008-12-10 2010-06-17 Cgi Pharmaceuticals, Inc. Certain substituted amides, method of making, and method of use thereof
ES2443948T3 (es) 2008-12-19 2014-02-21 Bristol-Myers Squibb Company Compuestos de carbazol carboxamida útiles como inhibidores de quinasas
US8299077B2 (en) 2009-03-02 2012-10-30 Roche Palo Alto Llc Inhibitors of Bruton's tyrosine kinase
ES2513915T3 (es) 2009-04-24 2014-10-27 F. Hoffmann-La Roche Ag Inhibidores de la tirosina quinasa de Bruton
EP2440204B1 (en) 2009-06-12 2013-12-18 Bristol-Myers Squibb Company Nicotinamide compounds useful as kinase modulators
WO2011019780A1 (en) 2009-08-11 2011-02-17 Bristol-Myers Squibb Company Azaindazoles as btk kinase modulators and use thereof
NZ598985A (en) * 2009-09-04 2013-07-26 Biogen Idec Inc Bruton's tyrosine kinase inhibitors
US7741330B1 (en) 2009-10-12 2010-06-22 Pharmacyclics, Inc. Pyrazolo-pyrimidine inhibitors of Bruton's tyrosine kinase
PE20121519A1 (es) 2010-01-27 2012-12-02 Boehringer Ingelheim Int Compuestos de pirazol como antagonistas de crth2
WO2012136343A1 (en) * 2011-04-05 2012-10-11 Eth Zurich Droplet dispensing device and light source comprising such a droplet dispensing device
CN103732596B (zh) * 2011-07-08 2016-06-01 诺华股份有限公司 吡咯并嘧啶衍生物
BR112014003582A2 (pt) 2011-08-17 2017-03-14 Hoffmann La Roche inibidores da tirosina quinase de bruton

Also Published As

Publication number Publication date
US9233983B2 (en) 2016-01-12
ZA201407341B (en) 2015-06-24
CN104662018B (zh) 2017-10-24
CA2869954A1 (en) 2013-10-24
CA2869954C (en) 2023-01-03
EP2838898A1 (en) 2015-02-25
CN104662018A (zh) 2015-05-27
JP6182593B2 (ja) 2017-08-16
AU2013250726A1 (en) 2014-10-09
JP2015514749A (ja) 2015-05-21
AU2013250726B2 (en) 2017-01-05
US20150064196A1 (en) 2015-03-05
EP2838898B1 (en) 2017-01-18
IL235146A (en) 2017-07-31
WO2013157022A1 (en) 2013-10-24

Similar Documents

Publication Publication Date Title
IN2012CH01573A (ja)
MX354412B (es) Composiciones y metodos para la produccion de compuestos de pirimidina con actividad inhibidora de tirosina cinasa de bruton.
PH12018502125A1 (en) Bipyrazole derivatives as jak inhibitors
IN2015DN02008A (ja)
PH12016501440A1 (en) Novel heterocyclic compounds
AU2011325657B2 (en) Novel 6-arylamino pyridone carboxamide as MEK inhibitors
MX2018003008A (es) Heteroarilos sustituidos con pirazolilo y su uso como medicamentos.
MX2015001715A (es) Compuestos de pirrolopirimidina novedosos como inhibidores de proteinas quinasas.
SG194728A1 (en) Inhibitors of bruton's tyrosine kinase
EA201492250A1 (ru) Гетероциклическое соединение
NZ629432A (en) Heterocyclyl compounds as mek inhibitors
MX2014005285A (es) Compuestos biciclicos de piperazina.
MY143483A (en) Novel heterocyclic compounds useful for the treatment of inflammatory and allergic disorders
IN2014CN03265A (ja)
EA201592033A1 (ru) 3-(2-АМИНОПИРИМИДИН-4-ИЛ)-5-(3-ГИДРОКСИПРОПИНИЛ)-1H-ПИРРОЛО[2,3-c]ПИРИДИНОВЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ NIK ДЛЯ ЛЕЧЕНИЯ РАКА
NZ601267A (en) Fused heteroaromatic pyrrolidinones as syk inhibitors
MX2013012776A (es) Inhibidores de la tirosina cinasa de bazo que contienen aminopiridina.
MX349372B (es) Inhibidores de la tirosina-cinasa de bruton.
WO2014172513A3 (en) 3,5-(un)substituted-1h-pyrrolo[2,3-b]pyridine, 1h-pyrazolo[3,4-b]pyridine and 5h-pyrrolo [2-,3-b]pyrazine dual itk and jak3 kinase inhibitors
IN2014DN07885A (ja)
WO2014093230A3 (en) Compositions and methods for the production of pyrimidine and pyridine compounds with btk inhibitory activity
EA201700042A1 (ru) Соединения имидазопиридазина
TN2016000511A1 (en) 1, 3, 4-thiadiazole compounds and their use in treating cancer
MX2015010466A (es) Inhibidores de tirosina cinasa de bruton.
MX2015010983A (es) Inhibidores de tirosina-cinasa de bruton.